이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ekso Bionics Holdings 관리

관리 기준 확인 4/4

Ekso Bionics Holdings' CEO는 Scott Davis, Dec2022 에 임명되었습니다 의 임기는 1.5 년입니다. 총 연간 보상은 $ 637.02K, 58.9% 로 구성됩니다. 58.9% 급여 및 41.1% 보너스(회사 주식 및 옵션 포함). 는 $ 103.93K 가치에 해당하는 회사 주식의 0.57% 직접 소유합니다. 103.93K. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 3 년입니다.

주요 정보

Scott Davis

최고 경영자

US$637.0k

총 보상

CEO 급여 비율	58.9%
CEO 임기	1.5yrs
CEO 소유권	0.6%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	3yrs

최근 관리 업데이트

Recent updates

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

May 02

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Dec 20

Shareholders May Not Be So Generous With Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) CEO Compensation And Here's Why

Jun 04

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

May 26

What Is The Ownership Structure Like For Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)?

Feb 10

Ekso Bionics sees lower 2020 sales vs. 2019

Jan 13

Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?

Dec 23

CEO 보상 분석

Scott Davis 의 보수는 Ekso Bionics Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	US$637k	US$375k	-US$15m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$16m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	US$1m	US$370k	-US$15m

보상 대 시장: Scott 의 총 보상 ($USD 637.02K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: Scott 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Scott Davis (54 yo)

1.5yrs

테뉴어

US$637,020

보상

Mr. Scott G. Davis serves as Chief Executive Officer of Ekso Bionics Holdings, Inc. since December 04, 2022 and serves as Director since December 08, 2022, and also served as its President & Chief Operatin...

리더십 팀

이름	위치	테뉴어	보상	소유권
Scott Davis	CEO & Director	1.5yrs	US$637.02k	0.57% $ 109.7k
Jerome Wong	Corporate Controller	7.1yrs	US$726.08k	0.25% $ 47.5k
Jason Jones	Chief Operating Officer	1.4yrs	US$710.24k	0.27% $ 51.2k
Rachael Anderson	Global Director of Marketing & Strategic Growth	3.4yrs	데이터 없음	데이터 없음
Ann Cookson	Human Resources Director	2.2yrs	데이터 없음	데이터 없음
Foon Chwee	President of APAC	6.4yrs	데이터 없음	데이터 없음
Stephan Aderhold	Senior VP & GM of EMEA	2.4yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

경험이 풍부한 관리: EKSO 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Scott Davis	CEO & Director	1.5yrs	US$637.02k	0.57% $ 109.7k
Sherri Medina	Member of Advisory Council	no data	데이터 없음	데이터 없음
Hans Keirstead	Member of Advisory Council	no data	데이터 없음	데이터 없음
Mary Cloyd	Independent Director	3.5yrs	US$147.01k	0.78% $ 150.1k
Corinna Lathan	Lead Independent Director	2.5yrs	US$158.13k	0.81% $ 156.1k
Nancy Byl	Member of Advisory Council	no data	데이터 없음	데이터 없음
Tom Kelley	Member of Advisory Council	no data	데이터 없음	데이터 없음
Daniel Kraft	Member of Advisory Council	no data	US$72.21k	데이터 없음
Kel Bergmann	Member of Advisory Council	no data	데이터 없음	데이터 없음
Graham Creasey	Member of Advisory Council	no data	데이터 없음	데이터 없음
Suzy Kim	Member of Advisory Council	no data	데이터 없음	데이터 없음
Charles Li	Independent Director	6.3yrs	US$143.10k	0.44% $ 83.5k

3.0yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: EKSO 의 이사회는 경험(평균 재직 기간 3 년)으로 간주됩니다.

Ekso Bionics Holdings 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Executive Chairman of the Board recently sold US$66k worth of stock

High number of new and inexperienced directors

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Recent updates

Ekso Bionics Holdings, Inc. Appoints Deborah Lafer Scher to its Board of Directors

Consensus EPS estimates upgraded to US$0.43 loss, revenue downgraded

Price target increased by 8.1% to US$10.00

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Forecast to breakeven in 2026

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 06, 2024

Ekso Bionics Holdings, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Consensus EPS estimates fall by 145%

Price target decreased by 7.5% to US$9.25

No longer forecast to breakeven

Full year 2023 earnings: EPS misses analyst expectations

Ekso Bionics Holdings, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Consensus estimates of losses per share improve by 26%

Forecast to breakeven in 2026

Ekso Bionics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $4.6 million.

Ekso Bionics Holdings, Inc. Launches GaitCoach Software for EksoNR

Ekso Bionics Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023

Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. Receives CMS Coding Approval for Ekso Indego Personal

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ekso Bionics Holdings, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Ekso Bionics Holdings, Inc. Receives Non-Compliance Notice from Nasdaq

Consensus revenue estimates increase by 12%, EPS downgraded

New major risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q2, 2023 Results on Jul 27, 2023

New minor risk - Share price stability

Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)

Executive Chairman of the Board recently sold US$66k worth of stock

Consensus EPS estimates fall by 40%

High number of new and inexperienced directors

No longer forecast to breakeven

Full year 2022 earnings released: US$1.16 loss per share (vs US$0.80 loss in FY 2021)

Forecast to breakeven in 2025

Ekso Bionics Holdings, Inc Announces Director Changes

Ekso Bionics Holdings, Inc. acquired Human Motion and Control Business Unit of Parker Hannifin Corporation for $10 million.

Price target decreased to US$9.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ekso Bionics Holdings, Inc. Approves Appointment of Jerome Wong as Corporate Secretary and Principal Financial Officer

Ekso Bionics Holdings, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Ekso Bionics: Fragile Opportunity

Second quarter 2022 earnings: EPS exceeds analyst expectations

Ekso Bionics Holdings, Inc. to Report Q2, 2022 Results on Jul 28, 2022

Is Ekso Bionics Holdings (NASDAQ:EKSO) A Risky Investment?

Ekso Bionics Holdings, Inc. Receives FDA Clearance to Market Its Eksonr(Tm) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Ekso Bionics Holdings, Inc. Announces Chief Financial Officer Changes

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 09, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Ekso Bionics Holdings, Inc. to Report Q1, 2022 Results on Apr 28, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Ekso Bionics Holdings, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Health Check: How Prudently Does Ekso Bionics Holdings (NASDAQ:EKSO) Use Debt?

Ekso Bionics: Expecting More Of The Same

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.30 profit in 3Q 2020)

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

Second quarter 2021 earnings released: US$0.10 loss per share (vs US$1.88 loss in 2Q 2020)

Ekso Bionics: Have Robot, Might Travel

Shareholders May Not Be So Generous With Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) CEO Compensation And Here's Why

Is Ekso Bionics Holdings (NASDAQ:EKSO) Weighed On By Its Debt Load?

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.44 loss in 1Q 2020)

Director has left the company

Ekso Bionics Holdings, Inc., Annual General Meeting, Jun 10, 2021

Full year 2020 earnings released: US$2.21 loss per share (vs US$2.53 loss in FY 2019)